πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 71 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11602515

Pharmaceutical compositions comprising dimethyl fumarate

Almirall, S.A. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11000517

Dosage and formulation

Almirall, S.A. Β· Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10759793

2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors

Almirall, S.A. Β· Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10588895

Quinuclidine derivatives and medicinal compositions containing the same

Almirall, S.A. Β· Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10456390

Combinations comprising MABA compounds and corticosteroids

Almirall, S.A. Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10300072

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10214509

Amino-substituted heterocyclic derivatives as sodium channel inhibitors

Almirall, S.A. Β· Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10173985

Aminoindazole derivatives as sodium channel inhibitors

Almirall, S.A. Β· Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10085974

Dosage and formulation

Almirall, S.A. Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10034867

Quinuclidine derivatives and medicinal compositions containing the same

Almirall, S.A. Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005771

Bicyclic derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

Almirall, S.A. Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9907807

Topical pharmaceutical compositions

Almirall, S.A. Β· Granted Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9757383

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9737520

Aclidinium for use in improving the quality of sleep in respiratory patients

Almirall, S.A. Β· Granted Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9687478

Quinuclidine derivatives and medicinal compositions containing the same

Almirall, S.A. Β· Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9643961

Cyclohexylamine derivatives having Ξ²2 adrenergic antagonist and M3 muscarinic antagonist a

Almirall, S.A. Β· Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9579316

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscar

Almirall, S.A. Β· Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9562039

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both Ξ²2 adr

Almirall, S.A. Β· Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9549934

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9518050

Cyclohexyl and quinuclidinyl carbamate derivatives having Ξ²2 adrenergic agonist and M3 mus

Almirall, S.A. Β· Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9388189

Pyrrolotriazinone derivatives as PI3K inhibitors

Almirall, S.A. Β· Granted Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9346759

Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydr

Almirall, S.A. Β· Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340547

Pyrrolotriazinone derivatives as inhibitors P13K

Almirall, S.A. Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9333195

Quinuclidine derivatives and medicinal compositions containing the same

Almirall, S.A. Β· Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted